November 17, 2016 - By Vivian Park · 0 Comments
Ibio Inc (NYSEMKT:IBIO) institutional sentiment decreased to 0.83 in 2016 Q2. Its down -0.57, from 1.4 in 2016Q1. The ratio is negative, as 5 investment managers increased and opened new positions, while 6 reduced and sold positions in Ibio Inc. The investment managers in our partner’s database now own: 2.88 million shares, down from 2.95 million shares in 2016Q1. Also, the number of investment managers holding Ibio Inc in their top 10 positions was flat from 0 to 0 for the same number . Sold All: 4 Reduced: 2 Increased: 3 New Position: 2.
iBio, Inc. is a biotechnology company. The company has a market cap of $51.13 million. The Firm is focused on commercializing its technologies and product candidates and providing product development and manufacturing services to clients and collaborators. It currently has negative earnings. The Company’s technologies include iBioLaunch technology and iBioModulator.
About 46,905 shares traded hands. Ibio Inc (NYSEMKT:IBIO) has declined 15.00% since April 15, 2016 and is downtrending. It has underperformed by 19.62% the S&P500.
According to Zacks Investment Research, “Ibio Inc., formerly known as iBioPharma Inc., is a biopharmaceutical company that primarily focuses on developing vaccines and therapeutic proteins based upon its plant-based iBioLaunch platform technology. The Company’s hydroponically grown green plants can be used for the development and manufacture of proteins applicable to a range of disease agents, such as influenza, sleeping sickness, anthrax, plague, human papillomavirus and veterinary influenza applications. IBio, Inc. is headquartered in Newark, Delaware.”
Signaturefd Llc holds 0.02% of its portfolio in Ibio Inc for 152,910 shares. Bank Of America Corp De owns 233 shares or 0% of their US portfolio. Moreover, Bank Of New York Mellon Corp has 0% invested in the company for 85,424 shares. The Delaware-based Blackrock Advisors Llc has invested 0% in the stock. Blackrock Fund Advisors, a California-based fund reported 15,313 shares.#img1#
iBio, Inc., incorporated on April 17, 2008, is a biotechnology company. The Firm is focused on commercializing its technologies and product candidates and providing product development and manufacturing services to clients and collaborators. The Company’s technologies include iBioLaunch technology and iBioModulator. The Company’s technologies constitute a transformative platform for development and production of biologics in hydroponically grown green plants. The Firm is focused on the commercialization of its plant protein expression technologies for vaccines and therapeutic proteins and on developing and commercializing select biopharmaceutical product candidates. The Company’s technologies include the natural protein production capability that plants use to sustain their own growth, and direct it instead to produce proteins for a range of applications, including for vaccines and biopharmaceuticals. The Company’s technology is applicable in a range of product candidates, including products against fibrotic diseases, vaccines, enzyme replacements, monoclonal antibodies, and recombinant versions of marketed products that are derived from human blood plasma.
More notable recent Ibio Inc (NYSEMKT:IBIO) news were published by: Marketwired.com which released: “iBio, Inc. Holds Annual Meeting in College Station, Texas” on April 07, 2016, also Streetinsider.com with their article: “iBio, Inc. (IBIO), Eastern Capital Enter JV to Develop Plant-Made Pharmaceuticals” published on January 14, 2016, Marketwired.com published: “iBio, Inc. Receives FDA Orphan Drug Designation for Fibrosis Product Candidate” on July 05, 2016. More interesting news about Ibio Inc (NYSEMKT:IBIO) were released by: Streetinsider.com and their article: “iBio, Inc. (IBIO) Announces Publication of Encouraging Protein Candidate Data …” published on September 21, 2015 as well as Streetinsider.com‘s news article titled: “iBio, Inc. (IBIO) Announces US Patent for Influenza Therapeutic” with publication date: August 11, 2015.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.
By Vivian Park